Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Scripps News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 15d ago.
Quick answers
Why is "Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- Could this drug be the next Ozempic? Lilly reports dramatic trial results Scripps News · 17d ago
Topics
Related trends
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
6-minute daily habit could help Ozempic users preserve muscle, expert says
A 40-week study found that resistance training helped people taking tirzepatide lose 25% less lean tissue while improving strength by 10%.